Shionogi to Present In Vitro and Real-World Data at IDWeek 2021 Demonstrating Activity of FETCROJA® (cefiderocol) Against Gram-Negative Pathogens
Shionogi & Co., Ltd. (hereafter Shionogi) today announces that 11 abstracts on FETCROJA (cefiderocol) will be shared at IDWeek.
- Shionogi & Co., Ltd. (hereafter Shionogi) today announces that 11 abstracts on FETCROJA (cefiderocol) will be shared at IDWeek.
- Abstracts will be available in the IDWeek Interactive Program and include:
Poster #1058: In Vitro and in Vivo Antibacterial Activity of Cefiderocol against Burkholderia spp. - Cefiderocol is a siderophore cephalosporin antibiotic with a novel mechanism for penetrating the outer cell membrane of Gram-negative pathogens by acting as a siderophore.
- Shionogi has a strong heritage in the field of anti-infectives and has been developing antimicrobial therapies for more than 60 years.